Navigation Links
Synthetic Biologics Reports Third Quarter 2012 Financial Results
Date:11/14/2012

™ and LEAP™ are registered trademarks of Intrexon Corporation.

This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our continued focus of our efforts in the field of synthetic biology and advancing our clinical programs and the expected size of the future market for sales of therapies for CDI and Acinetobacter. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, a failure to receive the necessary regulatory approvals for commercialization of our therapeutics, a failure of our clinical trials to be commenced or completed on time or to achieve desired results, a failure of our clinical trials to receive anticipated funding, a failure of gene therapy to receive market acceptance, a failure of our monoclonal antibodies for the treatment of infectious diseases to be successfully developed or commercialized, our inability to maintain our licensing agreements, including our agreement with Intrexon, our inability to successfully integrate new management, or a failure by us or our strategic partners to successfully commercialize products and other factors described in Synthetic Biologics' report on Form 10-K/A for the year ended December 31, 2011 and any other
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
2. Taming mavericks: Stanford researchers use synthetic magnetism to control light
3. Synthetic Biologics Completes $10.8 Million Private Placement Financing
4. Synthetic Biologics Announces $10.8 Million Financing
5. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
6. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
7. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
8. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
9. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
10. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
11. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... TRIANGLE PARK, N.C., USA (PRWEB) May 17, 2013 ...     Green Globes Certified for sustainability , ... and insect pressures , Syngenta ... opening celebration today at the company’s RTP Innovation Center. ... Lab allows company researchers to simulate any agricultural climate ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to ... Switzerland -based Kenta Biotech to ... antibody (mAb) products, and technologies. This asset portfolio ... treatment of infections by common pathogens including drug ... Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... May 17, 2013 RURO Inc. ... version 4.1, a versatile refinement to the smart ... solution, improves its advanced methodical management for transgenic ... ezColony 4.1. The network-based platform provides user access ... research. While continuing to emphasize streamlined tasks, such ...
(Date:5/16/2013)... The Stirling Ultracold Model SU780U ultra-low ... USA, won the Outstanding New Product Award presented on ... and Environmental Repositories (ISBER) at their annual meeting in ... recognizes the company’s development and introduction of the world’s ... was presented to Global Cooling’s CEO Neill Lane by ...
Breaking Biology Technology:Syngenta Opens Unique $72 Million Advanced Crop Lab 2Syngenta Opens Unique $72 Million Advanced Crop Lab 3Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2Stirling Ultracold Ultra-Low Freezer Wins 2013 Outstanding New Product Award at International Biorepository Conference, Sydney, Australia 2
... the accelerated development of new, safe and effective ... US and around the world, will become greater ... State University and Quintiles ( www.quintiles.com ), a ... leader in managing clinical research. The ...
... potential to save tens of thousands of lives each ... at the University of Massachusetts and the Serum Institute ... results from a Phase 1 study. The recently completed ... in protective antibody levels in the serum of treated ...
... ultrafine coal slurry has been successfully tested at the ... technology offers the possibility of reducing the coal slurry ... this new technology was presented Sept. 15 at the ... Cleaning coal after it has been mined is done ...
Cached Biology Technology:Drug Development in Arizona Gets Boost Following ASU-Quintiles Agreement 2New treatment for rabies advances after successful phase 1 trial in India 2New treatment for rabies advances after successful phase 1 trial in India 3Commercial-scale test of new technology to recover coal from sludge successful 2Commercial-scale test of new technology to recover coal from sludge successful 3
(Date:5/16/2013)... a commitment to the support of underrepresented minority ... Foundation has announced the inaugural AGA Investing in ... by the National Institute of Diabetes and Digestive ... underrepresented minority students to further their research careers ... establishing this new award, AGA demonstrates its commitment ...
(Date:5/16/2013)... used ancient shorelines to predict the stability of today,s largest ... shoreline from three million years ago, for example when ... to be evidence of a high sea level due to ... many scientists to think that if the world,s largest ice ... the same in our modern, progressively warming world. , ...
(Date:5/16/2013)... May 16, 2013 The relationship between the ... has not been clear. Schizophrenia is commonly associated ... There are clues that reduced IQ may be ... example, reduced cognitive ability may precede the onset ... present in healthy relatives of people diagnosed with ...
Breaking Biology News(10 mins):Underrepresented minority students receive fellowships in digestive disease and nutrition research 2World's biggest ice sheets likely more stable than previously believed 2Genetic risk for schizophrenia is connected to reduced IQ 2
... reporting the first use of ordinary cotton thread and ... device microscopic technology that can transport fluids for ... chips shrink room-sized diagnostic testing equipment down to the ... in medicine, environmental sensing, and other areas. Their study ...
... the ethical dilemma involved in using human embryonic stem ... In particular, they are looking for drug-like chemical compounds ... cells now obtained from human embryos. That,s the topic ... (C&EN), ACS, weekly newsmagazine. C&EN Associate Editor Sarah ...
... including international researchers with a scientist from Cardiff University, ... panda,s unusual biological traits, including its famously restricted diet. ... genome for the first time and now, the genetic ... for the endangered species. Giant pandas are ...
Cached Biology News:Giant panda genome reveals new insights into the bear's bamboo diet 2
Mouse monoclonal [050-04] to C2 ( Abpromise for all tested applications). entrezGeneID: 717 SwissProtID: P06681...
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
...
AADAC Immunogen: AADAC (NP_001077, 201 a.a. ~ 301 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Biology Products: